NEUROSEARCH

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Investor News

NeuroSearch to present at the Canaccord Adams annual Diabetes and Obesity Conference in New York

- ***The focus of the presentation will be on tesofensine, the company's highly efficacious phase II/III anti-obesity drug***

Copenhagen, 4 May 2009 – NeuroSearch has been invited to present at this year's annual Canaccord Adams Diabetes and Obesity Conference to be held

Tuesday, 12 May 2009 at 8:00 am – 5:00 pm EST (2:00 pm – 11:00 pm CET)

at the InterContinental Barclay Hotel, 111 East 48th Street, in N.Y.

The presentation will be held by Flemming Pedersen, CEO of NeuroSearch, who will also conduct 1-on-1 meetings with investors, analysts and other market participants in relation to the conference.

In the presentation, Flemming Pedersen will provide broad insight into NeuroSearch's highly efficacious late-stage anti-obesity drug, tesofensine, which is ready for Phase III development. In a Phase II Proof of Concept study, 24 weeks' treatment with tesofensine demonstrated a placebo-corrected weight-loss of approximately 10%. Further, the results of an open-label extension study have demonstrated a sustainable weight-loss of 13-14% in average after a combined 48 weeks of treatment with tesofensine.

From the conference invitation:
Diabetes and obesity have grown into global epidemics. In recognizing the strong correlation between these two diseases as well as their role in the development of deadly co-morbidities, this conference is tailored to address the continuum of care in these diseases providing an insightful value add in capturing the current and future innovations in the marketplace.

Contact persons:
Flemming Pedersen, CEO, telephone + +45 4460 8214 or 45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4460 8212 or +45 4017 5103

Tesosensine – Novel anti-obesity drug
Tesofensine is a monoamine reuptake inhibitor which NeuroSearch has evaluated in Phase II studies with out-standing effect for the treatment of obesity. After six months of treatment, a weight loss of approx. 10% was obtained (TIPO-1 study) and a weight loss of approx. 13-14% was seen after 12 months of treatment (TIPO-4 study). NeuroSearch believes that these results make tesofensine one of the most effective anti-obesity products in late-stage development.

In October 2008, the results from TIPO-1 were published in the highly reputed international scientific journal The Lancet with the conclusions that tesofensine can produce a weight loss at least twice that of currently approved anti-obesity drugs and that it should be further evaluated in Phase III studies in order to prepare for market registration.

NeuroSearch has built up a substantial data package supporting the strong profile of tesofensine. This includes safety data from more than 1,400 individuals having received treatment with tesofensine and of these approx. 1,200 have received relevant therapeutic doses.

NeuroSearch will decide on the final Phase III development plan following planned interactions with both the FDA and EMEA in 2009.

NeuroSearch – Company profile

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company and GlaxoSmithKline and a license collaboration with Abbott. The drug pipeline comprises seven clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease (Phase II ready), ACR343 for schizophrenia (Phase II ready), ABT-560 for the treatment of various CNS disorders (Phase I) in collaboration with Abbott, and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.